


Predictive Biomarkers

Stratify patients that may benefit from your therapy


Discover and validate genetic signatures of response leveraging the extensive Solid Tumor PDX Models Collection.

Use Predictive Biomarkers to find models that match your genetic signatures of interest, or responder and non-responder populations. All from a richly diverse collection of human surrogate PDX models, available for immediate drug discovery efficacy studies.


- Determine or validate relevant gene signatures or pathways related to response.
- Perform "Phase II-like" PDX Mouse Clinical Trials to stratify patient responders and non-responders.
- Characterize potential biomarkers of response.
- Identify novel indications for existing drugs.
- Manage life cycle of existing treatments.
- Constantly growing diverse collection of PDX with patient-relevant mutations.



KRAS Mutation vs Activating Oncogenic Alleles for Cetuximab Sensitivity in CRC PDX Models



Per KRAS codons 12/13 mutation rule: wild type vs mutations.



Per the set of oncogenic alleles rule: wild type/KRAS G13D vs at least one activating allele on KRAS G12C/D/V, -Q61X, -A146T, NRAS Q61X, AKT1 L52R, PIK3CA E545K/-Q546L and BRAF V600E.

Get in touch



Sales

US: +1 858 622 2900
UK: +44 870 166 6234

busdev@crownbio.com
www.crownbio.com



Science

consultation@crownbio.com

